Lactose intolerance is a pathological condition characterised by abdominal symptoms caused by lactase deficiency ([@bib35]; [@bib37]). Lactose intolerance is an autosomal recessive condition related to two polymorphisms in the MCM6 gene ([@bib8]). The lowest reported prevalence is 2% in Scandinavia, whereas the prevalence in South America, Africa, and Asia is around 50%, increasing to 100% in some Asian countries ([@bib31]). Lactose-intolerant individuals can consume small amount of dairy products (yoghurt and cheese), or use enzyme substitutes ([@bib37]), but they are usually recommended to avoid dairy products. Lactose intolerance should not be mixed up with lactose malabsorption that is not a pathological condition but a normal human phenotype.

A previous study that examined the per capita milk consumption among 27 countries found that it was positively associated with ovarian cancer risk ([@bib4]); however, subsequent epidemiological studies gave inconsistent results ([@bib17]; [@bib10]; [@bib18]). In addition, the associations of dairy products with breast ([@bib2]; [@bib23]; [@bib24]; [@bib6]) and lung cancers ([@bib1]) ([@bib16]; [@bib34]) were also inconclusive. A recent review by the World Cancer Research Fund and American Institute of Cancer Research claimed no sufficient evidence to establish associations between dairy intake and breast cancer risk ([@bib38]). Measurement error may partly explain these inconclusive data because most studies defined dairy consumption using questionnaires. All the previous studies examined cancer risks among those with high consumption of dairy products, using those with low consumption as the reference group. Here, we examined this association by an alternative approach: determining whether low consumption of dairy products in individuals with lactose intolerance can protect against the development of these cancers. This study could be regarded as an application of Mendelian randomisation to epidemiology ([@bib27]). In addition, we examined the risk of cancer in the first-degree relatives (siblings and parents) of individuals with lactose intolerance to exclude potential confounding factors, which cannot be measured.

Methods
=======

Individuals with lactose intolerance were identified from four Swedish Registers: the Primary Health Care Registers covering the counties of Skåne (1987--2010) and Stockholm (2001--2007) and the national Swedish Hospital Discharge Register (1987--2010) and Outpatient Register (2001--2010). The Primary Health Care Register in Region Skåne, PaSIS, contains data on all individuals (around 1.2 million) living in Skåne and who visited primary health care between 1987 and 2010. The Primary Health Care Register in Stockholm covers 75 primary health care centres for the period 2001--2007. The Swedish Hospital Discharge Register was founded in 1964--1965 by the National Board of Health and Welfare, and it has had complete nationwide coverage since 1987. The Outpatient Register contains data on all visits to outpatient clinics in Sweden since 2001. Individuals with lactose intolerance were identified according to the International Classification of Diseases (ICD-9 code 271D and ICD-10 code E73). Individuals with secondary lactose intolerance (ICD-10 code E731) were excluded from the study.

We further linked the individuals with lactose intolerance to the Swedish Cancer Registry to identify all incident cases of cancer during the study period. The Swedish Cancer Registry was founded in 1958 and has close to 100% coverage at the present time ([@bib14]). All linkages were performed using individual national identification numbers, which were replaced with serial numbers in order to preserve anonymity. We identified the siblings and parents of individuals with lactose intolerance from the Swedish Multi-Generation Register ([@bib7]), which contains data on the biological parents of index persons registered in Sweden since 1961 and born in or since 1932.

We calculated person-years at risk among individuals with lactose intolerance from the date of birth, immigration, or 1 January 1961, whichever came last, until the date of diagnosis of cancer, death, emigration, or the end of the study period (31 December 2010), whichever came first. Standardised incidence ratios (SIRs) were calculated as the ratio of the observed and expected number of cases ([@bib3]; [@bib30]). The expected number of cases was calculated by using the population incidence rate for all individuals without lactose intolerance. Standardised incidence ratios were standardised by 5-year age group, sex (male and female), 5-year time period, and country of birth (Sweden, other European countries, and other countries) ([@bib9]). When calculating the SIRs for breast and ovarian cancers, additional adjustments were made for number of offspring (zero, one, two, and three or more) and age at first childbirth (\<25, 25--34, and 35+ years). Confidence intervals (95% ) for the SIRs were calculated assuming a Poisson distribution, and were rounded to the nearest two decimals ([@bib9]). All analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC, USA).

Results
=======

In [Table 1](#tbl1){ref-type="table"}, we present the basic characteristics of individuals with lactose intolerance and their first-degree relatives. A total of 22 788 individuals were identified with lactose intolerance in Sweden between 1987 and 2010. More women than men had lactose intolerance and the median age at diagnosis was 12 years. Most of the individuals with lactose intolerance (85%) were born in Sweden, and around 25% of them had at least one offspring during the study period.

During the 484 572 person-years of follow-up, the risks of lung (SIR=0.55), breast (SIR=0.79), and ovarian (SIR=0.61) cancers were statistically significantly decreased ([Table 2](#tbl2){ref-type="table"}). The risk of lung cancer was similar among men and women. In [Table 3](#tbl3){ref-type="table"}, we present the risk of lung, breast, and ovarian cancer among the siblings and parents of individuals with lactose intolerance. None of the cancer sites showed a significantly decreased or increased SIR.

Discussion
==========

In this population-based study, a total of 22 788 individuals were identified with lactose intolerance between 1987 and 2010. This is, to our knowledge, the first study to examine the association between lactose intolerance and lung, breast, and ovarian cancers. The main finding was that the risks of lung, breast, and ovarian cancers were significantly decreased among individuals with lactose intolerance, whereas the incidences in their siblings and parents were similar compared with the general population.

The significantly decreased risk of lung, breast, and ovarian cancers in lactose-intolerant individuals suggests that these associations could be due to the low consumption of lactose or lactose-containing products. Caloric restriction has been found to be associated with a lower incidence of breast and ovarian cancers ([@bib21]; [@bib22]; [@bib32]; [@bib40]). In addition, milk and other dairy products can contain high amounts of fats, particularly saturated fat, and some growth factors, such as insulin-like growth factor I (IGF-I), and these dietary components have been suggested to be associated with the development of various types of cancers ([@bib39]; [@bib12]; [@bib33]; [@bib19]; [@bib11]). Insulin-like growth factor I can promote tumour cell growth through low apoptosis, high cell proliferation, and angiogenesis ([@bib15]), and it was reported that high concentrations of IGF-I are associated with a greater risk of breast cancer ([@bib29], [@bib28]). Previous studies have found that high consumption of milk is associated with plasma IGF-I concentrations ([@bib13]; [@bib25]), suggesting that low consumption of milk and other dairy products among individuals with lactose intolerance may be associated with a lower risk of breast cancer. Furthermore, avoidance of milk may alter the human gut microbiome, which may affect the development of tumours ([@bib5]). However, we cannot exclude the protective effects on the development of cancers of other dietary patters, such as a consumption of plant milk ([@bib26]; [@bib36]), including soy and rice milks, which are often consumed by individuals with lactose intolerance. Moreover, whether the genetic variants found in lactose-intolerant individuals could confound the expression of other genes through linkage disequilibrium warrants investigation.

An important strength of this study is that all the data were retrieved from Swedish Registers with high quality and coverage. A recent review suggested that the diagnostic accuracy in Swedish Hospital Registers is high with a positive predictive value ranging between 85 and 95% ([@bib20]). In addition, the number of patients included is large enough to guarantee reliable risk estimates. The prospective study design and the completeness of the follow-up of patients are other major advantages of the present study. One limitation of this study is the lack of information on some individual-level risk factors, such as smoking, alcohol consumption, dietary habits, psychosocial factors, and sociocultural behaviours, as well as the lack of genetic or physiological testing on the diagnosis of lactose intolerance.

In summary, individuals with lactose intolerance had decreased risks of lung, breast, and ovarian cancers, which may be related to their specific dietary patterns, but the contributions from other confounding factors should not be neglected.
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###### Basic characteristics of individuals in Sweden with lactose intolerance and their first-degree relatives

                                            **First-degree relatives**                                     
  ----------------------------------------- ---------------------------- ------- -------- ------- -------- -------
  **Sex**                                                                                                  
  Male                                      9468                         41.5    16 602   50.6    18 323   49.4
  Female                                    13 320                       58.5    16 214   49.4    18 783   50.6
  **Year of birth**                                                                                        
  Before 1950                               2445                         10.7    1934     5.9     7523     20.3
  1950--1959                                1100                         4.8     1349     4.1     6543     17.6
  1960--1969                                1327                         5.8     1682     5.1     13 220   35.6
  1970--1979                                1726                         7.6     2912     8.9     8774     23.6
  1980--1989                                3190                         14.0    6666     20.3    1045     2.8
  1990--1999                                7687                         33.7    10 520   32.1    1        0.0
  2000--                                    5313                         23.3    7753     23.6              
  **Country of birth**                                                                                     
  Sweden                                    19 400                       85.1    30 341   92.5    29 468   79.4
  Other European countries                  1142                         5.0     810      2.5     3394     9.1
  Other                                     2246                         9.9     1665     5.1     4244     11.4
  **Number of offspring**                                                                                  
  0                                         16 971                       74.5    25 296   77.1    0         
  1                                         1586                         7.0     2185     6.7     3807     10.3
  2                                         2455                         10.8    3167     9.7     16 194   43.6
  3+                                        1776                         7.8     2168     6.6     17 105   46.1
  **Age at birth of first child (years)**                                                                  
  \<25                                      2483                         10.9    3368     10.3    14 068   37.9
  25--34                                    2897                         12.7    3707     11.3    20 290   54.7
  35+                                       437                          1.9     445      1.4     2748     7.4
  All                                       22 788                       100.0   32 816   100.0   37 106   100.0

###### Cancer risk in patients with lactose intolerance by gender

               **Male**   **Female**   **All**                                                                 
  ------------ ---------- ------------ --------- ------ ----- ---------- ------ ------ ----- ---------- ------ ------
  Lung         11         **0.51**     0.25      0.92   16    **0.58**   0.33   0.94   27    **0.55**   0.36   0.80
  Breast                                                118   **0.79**   0.65   0.94   118   **0.79**   0.65   0.94
  Ovary                                                 16    **0.61**   0.35   0.99   16    **0.61**   0.35   0.99
  All cancer   235        0.95         0.84      1.08   499   0.96       0.88   1.05   734   0.96       0.89   1.03

Abbreviations: CI=confidence interval; O=observed number of cases; SIR=standardised incidence ratio.

Bold type, 95% CI does not include 1.00.

###### Cancer risk among siblings and parents of patients with lactose intolerance

           **Sibling**   **Parent**                                     
  -------- ------------- ------------ ------ ------ ----- ------ ------ ------
  Lung     30            1.02         0.69   1.46   131   0.85   0.71   1.01
  Breast   90            1.02         0.82   1.26   337   0.92   0.83   1.03
  Ovary    13            0.91         0.48   1.56   47    0.88   0.65   1.17

Abbreviations: CI=confidence interval; O=observed number of cases; SIR=standardised incidence ratio.
